Iron depletion therapy must be carefully managed to avoid inducing hypoxia and subsequent upregulation of hypoxia‐inducible factor 1‐alpha (HIF‐1α), which can promote chemoresistance and tumor recurrence in glioblastoma (GBM). The gene discussed is HIF1A; the disease is glioblastoma.